Eli Lilly's Trading Volume Drops 23.15% to $2.109 Billion Ranking 22nd Amid SiteOne Therapeutics Acquisition

On May 28, 2025, Eli Lilly and Company (NYSE:LLY) experienced a significant decline in trading volume, with a total turnover of $2.109 billion, marking a 23.15% decrease from the previous day. This decline placed Eli Lilly at the 22nd position in terms of trading volume among all stocks for the day.

Eli Lilly and Company has announced its acquisition of SiteOne Therapeutics, a private biotech firm specializing in the development of small-molecule inhibitors targeting sodium channels. This strategic move is aimed at expanding Eli Lilly's neuroscience pipeline, particularly focusing on pain management therapies. The acquisition is valued at up to $1 billion, pending regulatory approval. SiteOne's lead drug candidate, STC-004, is designed to target NaV1.8, a sodium channel involved in pain transmission. The drug has shown promising results in Phase 1 trials, demonstrating rapid absorption and a favorable safety profile. Eli Lilly plans to advance STC-004 to Phase 2 testing for both acute and chronic peripheral pain conditions.

Eli Lilly's acquisition of SiteOne Therapeutics is part of a broader effort to develop non-opioid pain treatments. The company's current pipeline includes several programs in Phase 2 testing for various types of pain, such as mazisotine, LY3848575, and LY3857210. These therapies target different mechanisms involved in pain signaling, aiming to provide effective and addiction-free pain management options. The acquisition of SiteOne Therapeutics aligns with Eli Lilly's commitment to addressing the global burden of chronic pain and advancing novel pain therapies.